Skip to content

Intravitreal Triamcinolone for Acute Branch Retinal Vein Occlusion

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00370266
Enrollment
30
Registered
2006-08-31
Start date
2003-02-28
Completion date
2007-12-31
Last updated
2008-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Branch Retinal Vein Occlusion

Keywords

Macular edema, Branch retinal vein occlusion, Intravitreal triamcinolone, Macular thickness, Retinal neovascularization

Brief summary

The purpose of this study is to determine whether intraocular injection of triamcinolone is effective in the treatment of macular edema in acute branch retinal vein occlusion.

Detailed description

Intravitreal triamcinolone has recently been shown to have beneficial effect on chronic macular edema due to vein occlusion and preventive effect on neovascularization. Hypothetically, prevention of macular derangement by reducing the amount of edema from early phase after occlusion until restoration of collaterals seems to be helpful in these eyes. To our knowledge, no prospective randomized clinical trial, considering both macular changes and preventive effect on neovascularization has been published for intravitreal triamcinolone in acute branch retinal vein occlusion.

Interventions

DRUGTriamcinolone

Sponsors

Shahid Beheshti University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Eyes suffering from branch retinal vein occlusion with less than 2 months duration.

Exclusion criteria

* Monocularity, * Previous intraocular surgery or laser therapy * Glaucoma or ocular hypertension * Significant media opacity * Existence of traction on the macula * Visual acuity ≥20/40 * Signs of chronicity (such as cilioretinal and/or retinal shunt vessels)

Design outcomes

Primary

MeasureTime frame
Central macular thickness

Secondary

MeasureTime frame
Visual acuity
Retinal neovascularization
Intraocular pressure
Cataract progression

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026